Clinical Trial

WU 345: Immune Responses to Adjuvanted and Non-adjuvanted Seasonal Influenza Vaccines in the Lymphoid Tissues.

Study acronym: WU 345
Terminated Early Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
COVID pandemic No participant experiences (benefits, adverse events/adverse reactions)to report. There have been no safety concerns in either participant. No minor deviations to report
Summary
Healthy adults (18-49 years of age) with no previous influenza virus vaccination history for at least three years prior to enrollment will be recruited to participate in this study. All subjects will concomitantly receive a single dose of both Fluad® and Afluria® administered intramuscularly in opposite deltoid muscles. Blood samples collected at 9 visits (screening, baseline, days 7, 14, 28, 60, 90, 120 and 180, fine needle aspiration (FNAs) from axillary lymph nodes from both axillae at baseline, days 7, 14, 28, 60, 90, 120 and 180.
Trial Details
NCT Number NCT07386509
Lead Sponsor Washington University School of Medicine
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Conditions Healthy
Enrollment 2 participants
Start Date 2020-03-17
Primary Completion 2022-11-04 (estimated)
Study Completion 2022-11-04 (estimated)
Updated on ClinicalTrials.gov 2026-02-04